Prothero Louise, Sturt Jackie, de Souza Savia, Lempp Heidi
1Department of Inflammation Biology, School of Immunology and Microbial Sciences, Faculty of Life Sciences and Medicine, King's College London, 10 Cutcombe Road, Denmark Hill, London, SE5 9RJ UK.
2Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, 57 Waterloo Road, London, SE1 8WA UK.
BMC Rheumatol. 2019 Mar 28;3:12. doi: 10.1186/s41927-019-0057-8. eCollection 2019.
The TITRATE trial seeks to test whether intensive management is valuable in achieving disease remission in moderately active rheumatoid arthritis. Intensive management is a complex intervention consisting of: 1) 12 x monthly appointments, 2) tailored 'treatment support' based on motivational interviewing techniques, 3) optimised medication (including the opportunity for biologics), 4) provision of a Patient Handbook, and 5) shared treatment planning. This study aims to understand: a) patients' and practitioners' views on the feasibility and acceptability of intensive management, and b) patients' and practitioners' experience of receiving/providing intensive management.
A qualitative study, nested within a randomised controlled trial. Participants were patients ( = 15) in the intensive management arm of the trial and rheumatology practitioners ( = 16) providing the intensive management intervention, from 18/42 clinics across England. Data were collected via semi-structured interviews and analysed using thematic analysis and iterative categorization.
Monthly appointments were largely acceptable to both groups who cited several treatment benefits (e.g. regular review of medication, practitioners built close relationships with patients). Practitioners were 'fairly confident' using the motivational interviewing techniques. Learning to pace was the most commonly reported self-management technique that patients and healthcare professionals worked on together, followed by gaining control over pain and fatigue. Practitioners liked having the option to offer biologics to patients with moderate RA. Most patients found the optimised medication (following monthly joint assessment) helpful and side-effects experienced were resolved. Variation existed in the extent to which patients engaged with the Patient Handbook and shared treatment planning, with those who did engage doing so in the early stages.
Feedback from patient participants about the intensive management intervention was positive. They found increased medication helpful. Continuity of care with the same healthcare professional at regular intensive management sessions, and the treatment support provided, were highly rated. Feedback from practitioners indicated that intensive management training is feasible. Evidence from the interviews showed that some practitioners applied motivational interviewing techniques during standard care appointments and they would like the opportunity to address lifestyle issues with patients.
TITRATE试验旨在测试强化管理在实现中度活动性类风湿关节炎疾病缓解方面是否有价值。强化管理是一种复杂的干预措施,包括:1)每月12次预约;2)基于动机性访谈技术的量身定制的“治疗支持”;3)优化用药(包括使用生物制剂的机会);4)提供一本患者手册;5)共同制定治疗计划。本研究旨在了解:a)患者和从业者对强化管理的可行性和可接受性的看法;b)患者和从业者接受/提供强化管理的体验。
一项定性研究,嵌套于一项随机对照试验中。参与者为来自英格兰42家诊所中的18家诊所的试验强化管理组的患者(n = 15)和提供强化管理干预的风湿病从业者(n = 16)。通过半结构化访谈收集数据,并使用主题分析和迭代分类法进行分析。
两组对每月预约基本都能接受,他们列举了多项治疗益处(如定期复查用药情况、从业者与患者建立密切关系)。从业者对使用动机性访谈技术“相当有信心”。学会调整节奏是患者和医护人员共同开展的最常被提及的自我管理技巧,其次是控制疼痛和疲劳。从业者喜欢有向中度类风湿关节炎患者提供生物制剂的选择。大多数患者发现(每月关节评估后)优化用药很有帮助,且所经历的副作用得到了解决。患者参与患者手册和共同制定治疗计划的程度存在差异,参与的患者在早期阶段就参与了。
患者参与者对强化管理干预的反馈是积极的。他们发现增加用药很有帮助。在定期的强化管理环节中与同一名医护人员保持连续护理以及所提供的治疗支持得到了高度评价。从业者的反馈表明强化管理培训是可行的。访谈证据显示,一些从业者在标准护理预约期间应用了动机性访谈技术,他们希望有机会与患者讨论生活方式问题。